Intra-Cellular Therapies, Inc.
ITCI
Kedudukan dalam Saham
#1686
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on... Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on creating innovative treatments for conditions affecting the brain and nervous system. The company achieves this by targeting the intricate cellular communication pathways within the central nervous system, primarily operating in the United States. Its commercialized product is CAPLYTA, an approved therapy for schizophrenia in adult patients. Furthermore, the company maintains a robust development pipeline, including lumateperone, which is undergoing late-stage (Phase III) clinical trials for bipolar depression and is also being investigated for autism spectrum disorder and various sleep disturbances associated with neuropsychiatric and neurological illnesses. Other key drug candidates in its pipeline include Lenrispodun (ITI-214), aimed at treating Parkinson's disease and heart failure; ITI-1284-ODT-SL, designed to address neuropsychiatric disorders and behavioral challenges in dementia; and ITI-333, intended for substance use disorders, pain management, and co-occurring psychiatric conditions like depression and anxiety. Established in 2002, Intra-Cellular Therapies, Inc. has its headquarters situated in New York, New York.
Harga Saham
$131.87
Disegerakkan terakhir: 2025-04-02
Modal Pasaran
$12.68B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Intra-Cellular Therapies, Inc. (ITCI)
Kategori
Healthcare
Sejarah harga saham bagi Intra-Cellular Therapies, Inc. (ITCI)
Harga penutupan tertinggi: $131.87 pada 2025-04-01
Harga penutupan terendah: $18.58 pada 2014-01-01
Harga penutupan terendah: $18.58 pada 2014-01-01
Sejarah harga saham Intra-Cellular Therapies, Inc. dari 2014 hingga 2026
Prestasi harga saham tahunan
| Tahun | Prestasi |
|---|---|
| 2025 | 55.77% |
| 2024 | 28.97% |
| 2023 | 25.44% |
| 2022 | 22.29% |
| 2021 | 54.57% |
| 2020 | 49.37% |
| 2019 | 44.08% |
| 2018 | -15.24% |
| 2017 | -2.14% |
| 2016 | -71.45% |
| 2015 | 222.13% |
| 2014 | 0.00% |
Harga saham bagi syarikat atau pesaing serupa
| Syarikat | Harga saham | Perubahan 1thn% | Negara |
|---|---|---|---|
| $171.67 | - |
DE
|
|
| $161.15 | 20.52% |
DE
|
|
| $40.25 | 42.39% |
JP
|
|
| $212.49 | 24.09% |
CH
|
|
| $19.19 | -0.09% |
IN
|
